SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins selloff amid concerns over a reported Binance security breach is weighing on Strategy shares, with traders debating whether the crypto-market shock signals deeper trouble or a buying opportunity. Concerns about Strategys quarterly results and CFO transition add to the bearish discussion, while some investors expect a rebound.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths Medicare add-on reimbursement could decline sharply after the first quarter of 2027 has fueled concern about pricing and CorMedixs largest revenue driver, alongside a steep selloff. Traders disagree on whether the comments signal a lasting revenue threat or are preliminary, DaVita-specific estimates with limited visibility into future reimbursement and utilization.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has reached fresh 52-week highs, with traders focused on an expected Q3 earnings report and debating whether the rally reflects BRIUMVI growth expectations or speculative buyout hopes and short covering. The buyout talk remains unconfirmed, and the earnings date has not been officially confirmed.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak Q1 results, sharply reduced full-year outlook and dividend suspension have driven attention, as the company cited recession-level appliance demand and blamed the Iran war and collapsing consumer confidence. Many traders are alarmed by the worsening outlook and debt burden, while some see the selloff as an overreaction and are buying for a possible rebound.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

Weaker 2027 Medicare Advantage star ratings for Aetna are driving concern about lost bonus payments and future margin pressure. Traders are comparing CVSs weakness with Humanas rally on improved ratings, while debating whether the setback is already priced in.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Traders are focused on a possible update on Corvuss ALPS program around the ASH abstract release and a company call, though the timing and whether the data will be disclosed remain uncertain. Optimism about a potential catalyst is countered by concerns over past delays, managements limited updates and heavy short interest.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

RASONQUE (daraxonrasib), Revolution Medicines pancreatic cancer therapy, remains the main focus: traders cite its Phase 3 survival results and FDA approval as support for the companys commercial and broader RAS-drug pipeline prospects. Discussion is also divided over valuation and efficacy across KRAS subtypes, with some traders pointing to competition from selective G12D drugs such as Verastems VS-7375.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances updated NSCLC trial results and shift toward biomarker-selected lung-cancer studies are driving attention: the overall response rate was 24.6%, while a retrospective subgroup showed a stronger signal, but the lung-cancer filing is expected in 2027 and durability remains uncertain. Traders are divided between viewing the selloff as an overreaction to promising precision-treatment data and seeing a narrower, delayed opportunity compounded by managements confusing presentation.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples fiscal fourth-quarter earnings report is the focus, with traders debating whether its premium valuation can be justified amid memory-cost pressures and concerns about iPhone demand and upgrade cycles. Some expect a sharp post-report drop, while others view Apples restrained AI spending and relative resilience during the tech selloff as supporting its safe-haven appeal.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowheads interim ARO-MAPT resultsshowing substantial tau reduction and supporting subcutaneous delivery of RNAi to the central nervous systemare a major focus. Traders broadly view the data as encouraging platform validation, but many are frustrated that the share price has not reflected the positive results and debate whether the weakness is market-driven or a sell-the-news reaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are Medical Stocks Lagging  Agilon Health (AGL) This Year?

Here is how Agilon Health (AGL) and Arcturus Therapeutics (ARCT) have performed compared to their sector so far this year.

Is Agilon Health (AGL) Stock Outpacing Its Medical Peers This Year?

Here is how Agilon Health (AGL) and CRISPR Therapeutics AG (CRSP) have performed compared to their sector so far this year.

agilon health Sets Date to Report Third Quarter 2026 Financial Results

agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financial results for the third quarter 2026 after market close on Wednesday, November 4, 2026 and host a conference call at 4:30 p.m. ET to...

agilon health and The Jackson Clinic Advance Their Partnership Through Senior Health Connect ACO

agilon health (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced the expansion of its partnership with The Jackson Clinic, which will join one of agilons Senior Health Connect Accountable Care Organizations (ACOs). The Jackson Clinic...

Agilon Health is Now Oversold (AGL)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...

agilon health and Springfield Clinic Broaden Partnership Through Senior Health Connect ACO

agilon health (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced the expansion of its partnership with Springfield Clinic in Illinois, which will join one of agilons Senior Health Connect Accountable Care Organizations (ACOs...

This Ulta Beauty Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday

Analysts upgraded Pentair, Agilon Health, Etsy, Radiant Logistics and Ulta Beauty, raising or setting new price targets.read more...

agilon health and Family Practice Center Expand Relationship Through Senior Health Connect ACO

agilon health (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced the expansion of its relationship with Family Practice Center, PC (FPC) in Pennsylvania, which will join one of agilons Senior Health Connect Accountable Care...

Is Agilon Health (AGL) Outperforming Other Medical Stocks This Year?

Here is how Agilon Health (AGL) and Illumina (ILMN) have performed compared to their sector so far this year.

agilon health Announces Revised Presentation Time at the 2026 Jefferies Healthcare Services and Technology Conference

agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that its management team will now participate in a fireside chat at the 2026 Jefferies Healthcare Services and Technology Conference at 4:00pm ET on Monday...

Agilon Health, Inc. engages in the provision of healthcare services. It also provides capital, data, payor relationships, executive experience, and contract support that allow physician groups to take on the risk of total care for their patients. The company was founded by Ronald A. Williams and Veeral Desai in 2016 and is headquartered in Westerville, OH.

Agilon Health Inc

AGL Stock's On Track To Hit 9-Month Highs – Here’s Why Analysts And Retail Are Betting On Strong Upside

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>First-quarter revenue came in at $1.42 billion, beating Wall Street’s estimates of $1.38 billion, according to Fiscal.ai data.</li><li>Agilon raised its FY2026 revenue guidance to between $5.68 billion and $5.81 billion, up from its earlier forecast of $5.41 billion to $5.58 billion.</li><li>Jefferies upgraded AGL to ‘Buy’ from ‘Hold’ while increasing its price target by 75% to $48, according to The Fly.</li></ul>Shares of Agilon Health (AGL) surged more than 50% in pre-market trading on Thursday, drawing renewed bullish calls as analysts and investors bet on further upside after the company raised its full-year 2026 guidance and posted a first-quarter earnings beat.<a href="https://stocktwits.com/symbol/AGL">AGL shares</a> are on track to hit their highest levels since August 2025.<h2 class="st-heading-2">Q1 Beat, Raised Guidance, Drive Optimism On AGL Stock</h2>Q1 revenue came in at $1.42 billion, exceeding Wall Street’s estimates of $1.38 billion, according to Fiscal.ai data. Its earnings per share (EPS) of $2.94 far exceeded consensus estimates of $0.93.Agilon raised its FY2026 revenue guidance to between $5.68 billion and $5.81 billion, up from its earlier forecast of $5.41 billion to $5.58 billion. Adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) guidance was raised to between $10 million and $40 million, from the range of a loss of $15 million to a profit of $15 million.<h2 class="st-heading-2">Analysts Flag Strong Potential Upside For AGL Stock</h2>Jefferies upgraded the stock to ‘Buy’ from ‘Hold’ while increasing its price target by 75% to $48, according to The Fly. Analyst Jack Slevin cited “strong” results and “clear signs” of improved trend visibility for the “exceedingly positive” risk/reward set-up of the shares. He added that Agilon’s outlook has been improving as favorable Medicare Advantage rates are now set for 2026 and 2027.Deutsche Bank also upgraded the stock to ‘Buy’ from ‘Hold’ and raised its price target to $49 from $33. The firm said the improving macro environment and “compelling” share valuation were the primary reasons for the upgrade, following Agilon’s guidance raise.<h2 class="st-heading-2">AGL Stock: Retail Sees $100 On The Horizon</h2>Retail sentiment for AGL on Stocktwits flipped to ‘bullish’ from ‘bearish’ a day earlier, while message volumes increased by nearly 260% on the platform.One user said the road to $100 has “officially started.” The stock is currently trading at just below $42.<stembedurl>https://stocktwits.com/Simonyac/message/652554170</stembedurl>Another user highlighted the firm’s improving fundamentals, adding that the company is “definitely turning this around.”<stembedurl>https://stocktwits.com/Loveleaps55/message/652508718</stembedurl>AGL shares have gained around 55% so far in 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.

AGL shares were in focus on Thursday after receiving bullish brokerage calls following a full-year 2026 guidance raise.

Why Is AGL Stock Rising Today?

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$AGL Not selling anything until $150. Will re-evaluate after it hits that and get to review the guidance going forward.  Remember $150 is still equal to $6 pre-spilt(RS). This stock IPO’d at $20 ($500 post RS) and it’s has 4x the revenue now fe when it IPO’d. Company focused on profitability.  Good things to come

Am riam

$AGL $94ISH is resistance. Several times it hits that area +/- $, and retraces. Bulls need a close above that level to see if it can break the next resistance, $100.

Feed

News

Sentiment

Earnings

Fundamentals

Info

AGL Agilon Health Inc

Fundamentals

Latest AGL News